---
schema_version: "secwatch.filing_event.v1"
accession: "0001510964-21-000065"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2021-11-15T23:59:59+00:00"
generated_at: "2026-06-28T08:19:50.394489+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CV Sciences Q3 2021 revenue down 8% to $5.1M; cash drops to $1.7M

## Summary
- Revenue $5.1M vs $5.6M YoY (-8%); operating loss $3.0M vs $3.2M.
- Gross margin 46.2% (up 200 bps); retail stores 7,700 (up from 6,200).
- Cash balance $1.7M at quarter-end vs $4.5M at year-end.
- PPP loan of $2.9M forgiven; launched PlusCBD Reserve line.
- CEO cites CA AB 45 passage as favorable regulatory momentum for 2022.

## SEC filing metadata
- accession: 0001510964-21-000065
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2021-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000151096421000065/0001510964-21-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000151096421000065/cvsi-20211115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001510964-21-000065
- JSON: https://secwatch.observer/filing/0001510964-21-000065.json
- Plain text: https://secwatch.observer/filing/0001510964-21-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.